TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04230382

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnosis of diabetes (OGTT)
Description: Blood sample will be collected for glucose, HbA1c and magnesium. Standard OGTT will be conducted with 75g of glucose (repeated, if disgnostic).
Study: NCT00281840

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Bevacizumab IV over 30-90 minutes once every 2 weeks for up to 1 year. Bevacizumab, which stops 8 weeks before surgery, may restart 4 weeks after surgery and continue for 9 months in the absence of disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: docetaxel IV over 1 hour once a week for 8 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: 8-10 weeks after the completion of chemoradiotherapy, patients may undergo neck dissection

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: radiotherapy once daily, 5 days a week, for 8 weeks
Study: NCT03609970

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: UVR (Solar simulated radiation)
Description: 1.25 SED Solar simulated radiation twice weekly
Study: NCT03302130

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mood induction (using own memories)
Description: Subjects deliver three positive, three negative and three neutral memories 30 seconds reliving a memory - answering questions about the memory - reliving memory for 2 minutes during ASL-MRI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arterial spin labeling MRI
Description: Single PLD PCASL

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Physiological monitoring
Description: During MRI: heart rate, end-tidal CO2, respiratory rate and skin conductance
Study: NCT03933046

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PSG
Description: polysomnography and urine analaysis for protein levels
Study: NCT03166670

Intervention type: DIAGNOSTIC_TEST
Intervention: stool examination
Description: collection of stool specimen and microscopic examination for parasites

Intervention type: DIAGNOSTIC_TEST
Intervention: stool examination
Description: collection of stool specimen and microscopic examination for parasites

Intervention type: DIAGNOSTIC_TEST
Intervention: real time polymerase chain reaction
Description: evaluation of genotype of cryptosporidium in stool specimen

Intervention type: DIAGNOSTIC_TEST
Intervention: real time polymerase chain reaction
Description: evaluation of genotype of cryptosporidium in stool specimen
Study: NCT00912327

Intervention type: BIOLOGICAL
Intervention: Imprime PGG
Description: Imprime PGG, 4 mg/kg, i.v. over 2 hr, weekly in 6 week cycles and Cetuximab, initial dose will be 400 mg/m2 via i.v., and subsequent doses will be 250 mg/m2 via i.v., weekly in 6 week cycles

Intervention type: BIOLOGICAL
Intervention: Imprime PGG
Description: Imprime PGG, 4 mg/kg, i.v. over 2 hr, weekly in 6 week cycles and Cetuximab, initial dose will be 400 mg/m2 via i.v., and subsequent doses will be 250 mg/m2 via i.v., weekly in 6 week cycles
Study: NCT01494233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 250 mg LX1033 tablets
Description: 250 mg LX1033 tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 250 mg LX1033 tablets
Description: 250 mg LX1033 tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 250 mg LX1033 tablets
Description: 250 mg LX1033 tablets administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Matching placebo tablet administered orally
Study: NCT04846907

Intervention type: OTHER
Intervention: Web-based survey
Description: Eligible participants received emails or text messages with links to a REDCap-created and managed web-based questionnaire
Study: NCT00916617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bapineuzumab
Description: 5 mg/week subcutaneous bapineuzumab
Study: NCT04435522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Maraviroc will be administered for seven days. Biomarkers of disease will be checked at time of enrollment, during and at the conclusion of therapy. The cytokine panel will consist of CCL5, IL-6, and Chitinase 3-like 1(Chi3l1).
Study: NCT03093142

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham neurofeedback
Description: sham neurofeedback
Study: NCT01461694

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intense Pulsed Light (IPL)
Description: Half Face Treated with IPL

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Alexandrite Laser
Description: Half face treated with Alexandrite Laser
Study: NCT04293874

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Meal Plan
Description: Personalized dietary plans will be developed incorporating the NPAGCS, while personalizing the plan based upon anthropometric characteristics, gender, age and self-reported activity level upon entry into the investigation, goals, typical dietary consumption patterns, and food preferences. A trained research assistant will use the USDA MyPlate88 site (www.choosemyplate.gov) to enter participant characteristics and determine the appropriate calorie level. A daily checklist will be then generated outlining the number of daily servings that should be consumed for each food group. Information will also be provided regarding serving sizes for different foods in the respective food groups and education will be provided regarding tailoring personal dietary preferences to meet the guidelines. Participants will be provided with a printed copy of their meal plan and instructed to initiate it for a 8-week period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Meal Plan
Description: Personalized dietary plans will be developed incorporating the NPAGCS, while personalizing the plan based upon anthropometric characteristics, gender, age and self-reported activity level upon entry into the investigation, goals, typical dietary consumption patterns, and food preferences. A trained research assistant will use the USDA MyPlate88 site (www.choosemyplate.gov) to enter participant characteristics and determine the appropriate calorie level. A daily checklist will be then generated outlining the number of daily servings that should be consumed for each food group. Information will also be provided regarding serving sizes for different foods in the respective food groups and education will be provided regarding tailoring personal dietary preferences to meet the guidelines. Participants will be provided with a printed copy of their meal plan and instructed to initiate it for a 8-week period.
Study: NCT02661581

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Support
Description: The intervention is lifestyle change. First, the peer leaders will be trained how to conduct diabetes self-management education and support sessions. During the first 3 months, all the participants will attend the diabetes self-management education sessions. The participants in the intervention arm will also receive diabetes self-management support sessions as well. In the end of the first 3 months, the intervention group participants will receive weekly support sessions for 9 months.
Study: NCT01142739

Intervention type: OTHER
Intervention: Clinical variables
Description: Demography, disease duration, treatment duration, current treatment, daily intake of levodopa, Disease stage (Hoehn and Yahr, HY), motor score (UPDRS III) and dyskinesia severity (UPDRS IV). Biological variables.

Intervention type: OTHER
Intervention: Clinical variables
Description: Demography, Biological variables.

Intervention type: OTHER
Intervention: Clinical variables
Description: Eye movement recordings : non-invasive infra-red camera oculometry (EyeBrain) before and after (only parkinson's disease group) levodopa(10 to 15 minute/recording)
Study: NCT05137639

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)
Description: PRF was only applied in the experimental arm to improve wound bed conditions
Study: NCT01778309

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: n-acetylcysteine supplementation
Description: n-acetylcysteine administration: 20 mg//kg/day, orally, daily for eight days following exercise~placebo administration: 500 mL orally, daily for eight days following exercise
Study: NCT00757198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remifentanil
Description: remifentanil infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanil
Description: remifentanil infusion
Study: NCT04355767

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma
Description: SARS-CoV-2 convalescent plasma with neutralizing SARS-CoV2 antibodies titers of ≥1:160 administered via intravenous (IV) infusion.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline with multivitamin administered via intravenous (IV) infusion..
Study: NCT03141346

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sugar reduction health education program
Description: A health education program incorporating sugar reduction education and monitoring provided by a trained health educator over 24 months. The intervention program will be delivered by the health educator during in-person home visits, or virtually via phone or video calls.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sugar reduction health education program
Description: A health education program incorporating sugar reduction education and monitoring provided by a trained health educator over 24 months. The intervention program will be delivered by the health educator during in-person home visits, or virtually via phone or video calls.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control health education program
Description: Control health education program provided by a trained health educator over 24 months. The intervention program will be delivered by the health educator during in-person home visits, or virtually via phone or video calls.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home water delivery
Description: Home delivery of bottled water administered over 24 months
Study: NCT03328286

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly group meeting w/psychotherapist
Description: Introduce a Psychotherapist in a work Integration program to further support Young adults in Job search and at the same time offering psychotherapeutic counselling. The participants will have a weekly meeting lasting 1.5 hour and additionally the can have 5 private counselling sessions with the psychotherapist if they wish
Study: NCT00488007

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing aids used : PHONAK Savia and Valeo
Description: 5 hours per day during the first 6 months (active or inactive upon randomization) 5 hours per day during the last 6 months (active)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Hearing aids used : PHONAK Savia and Valeo
Description: 5 hours per day during the first 6 months (active or inactive upon randomization) 5 hours per day during the last 6 months (active)
Study: NCT02662556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sufentanil sublingual tablet 30 mcg
Description: sufentanil sublingual tablet 30 mcg as needed for pain management, but no more frequently than every 60 minutes, for up to 12 hours.
Study: NCT03383302

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Description: Patients will receive a total of 54 Gy if delivered in 3 fractions, 55 Gy if delivered in 5 fractions or 60 Gy if delivered in 8 fractions.
Study: NCT04293874

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Omega-3LC intervention
Description: Following randomization, participants will be provided with fish to be consumed for 6 weeks. As a component of the dietary intervention, participants in high and low omega-3LC group will be provided with frozen, wild caught salmon (or if they dislike salmon, prepackaged, individual use foil packs of chunk light tuna). Salmon and chunk light tuna were chosen due to high omega-3LC content, low methylmercury content, low cost and ease of use. Vacuum packed, frozen salmon will be delivered to participants in large freezer bags and instructed to arrange visit times to ensure they can go directly home following the visit. Instructions for safe storage, fish handling and recipes to avoid fatigue of fish will be also be provided to participants when they receive the fish.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Omega-3LC intervention
Description: Following randomization, participants will be provided with fish to be consumed for 6 weeks. As a component of the dietary intervention, participants in high and low omega-3LC group will be provided with frozen, wild caught salmon (or if they dislike salmon, prepackaged, individual use foil packs of chunk light tuna). Salmon and chunk light tuna were chosen due to high omega-3LC content, low methylmercury content, low cost and ease of use. Vacuum packed, frozen salmon will be delivered to participants in large freezer bags and instructed to arrange visit times to ensure they can go directly home following the visit. Instructions for safe storage, fish handling and recipes to avoid fatigue of fish will be also be provided to participants when they receive the fish.
Study: NCT03620708

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Participants are provided with a 35 minute counseling session designed to increase motivation to quit smoking and then provided with a written referral for tobacco dependence treatment.
Study: NCT03383302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody, that binds to the PD-1 receptor and blocks interaction with its ligands PD-L1 and PD-L2. Nivolumab will be administered intravenously at a flat dose of 240 mg q2w over 30 minutes for 13 cycles followed by 480mg q4w over 60 minutes for 7 cycles, until 20 cycles in total to complete (a minimum of 1 year of treatment if no delays are encountered).
Study: NCT02743598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Study: NCT04120701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: Patients receive adjuvant chemotherapy every 2 weeks during 6 months: FOLFOX6m (5-FU, leucovorin and oxaliplatin).
Study: NCT01141569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gamma-Secretase Inhibitor RO4929097
Description: Given PO
Study: NCT03620708

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement Therapy Sampling
Description: Participants are provided with a two-week sample of over-the-counter nicotine replacement therapy (i.e., nicotine lozenge and nicotine patch) and then provided with a written referral for tobacco dependence treatment.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Referral Only
Description: Participants are provided with a written referral for tobacco dependence treatment.
Study: NCT03707223

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Interfaces Program
Description: career development program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IPS
Description: supported employment using the individual placement and support (IPS) model
Study: NCT00655993

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: simvastatin
Description: 40 mg po daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Description: 40 mg po daily
Study: NCT01141569

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00405561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMT2003
Study: NCT01696123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLC601
Description: It was described
Study: NCT02371538

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Donor Breastmilk
Description: Donor breastmilk will be obtained from the Mother's Milk Bank of New England.
Study: NCT03075371

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: 75 g of glucose dissolved in 300 ml of water

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 300 ml of tap water
Study: NCT02424799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2646264 0.5% topical cream
Description: GSK2646264 0.5% topical cream is supplied as white-to-off-white aqueous cream stored in amber glass jars

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2646264 0.5% topical cream
Description: GSK2646264 0.5% topical cream is supplied as white-to-off-white aqueous cream stored in amber glass jars

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2646264 0.5% topical cream
Description: GSK2646264 0.5% topical cream is supplied as white-to-off-white aqueous cream stored in amber glass jars

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2646264 0.5% topical cream
Description: GSK2646264 0.5% topical cream is supplied as white-to-off-white aqueous cream stored in amber glass jars

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2646264 1% topical cream
Description: GSK2646264 1% topical cream is supplied as white-to-off-white aqueous cream stored in amber glass jars

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2646264 1% topical cream
Description: GSK2646264 1% topical cream is supplied as white-to-off-white aqueous cream stored in amber glass jars

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2646264 1% topical cream
Description: GSK2646264 1% topical cream is supplied as white-to-off-white aqueous cream stored in amber glass jars

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo topical cream is supplied as white-to-off-white aqueous cream stored in amber glass jars

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo topical cream is supplied as white-to-off-white aqueous cream stored in amber glass jars

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo topical cream is supplied as white-to-off-white aqueous cream stored in amber glass jars

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo topical cream is supplied as white-to-off-white aqueous cream stored in amber glass jars
Study: NCT00998231

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: blood sample
Description: Blood collections and peripheral blood mononuclear cells extraction will be operated after each evaluation and followed by RNA extraction, reverse transcription and gene expression quantification by real-time PCR.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: blood sample
Description: Blood collections and peripheral blood mononuclear cells extraction will be operated after each evaluation and followed by RNA extraction, reverse transcription and gene expression quantification by real-time PCR.
Study: NCT00538473

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' influenza vaccine GSK576389A
Description: Single dose, intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix™
Description: Single dose, intramuscular injection
Study: NCT01139242

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Body & Soul nutritional intervention
Description: Pastoral and peer counseling, and church activities/menus to promote increased fruit and vegetable consumption among church members.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: newsletters and peer counseling
Description: Four tailored newsletters and peer counseling calls to promote CRC screening in church members who are out-of-date with screening. Four tailored newsletters and peer counseling calls to others to increase physical activity.
Study: NCT01829490

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 85A
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 85A
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 85A
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 85A
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA85A
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA85A
Description: Intramuscular injection
Study: NCT01145573

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium or Placebo
Description: Participants are randomized to take either 1000mg of calcium or placebo from week 16 of pregnancy until delivery.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium or Placebo
Description: Participants are randomized to take either 1000mg of calcium or placebo from week 16 of pregnancy until delivery.
Study: NCT03166969

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Holter 21 days
Study: NCT02765958

Intervention type: DEVICE
Intervention: portable ECG devise

Intervention type: DEVICE
Intervention: portable ECG devise
Study: NCT03162120

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine plus Metoprolol Combination
Description: Ranolazine plus Metoprolol Combination in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FlecainidE pluS Metoprolol Combination
Description: FlecainidE pluS Metoprolol Combination in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation
Study: NCT01205373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 671800
Description: High dose oral drinking solution